Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 5, 2009, Pages 340-346

  ThØgersen, Anna M ^a,b   Nilsson, Torbjörn K ^c   Weinehall, Lars ^a   Boman, Kurt ^d   Eliasson, Mats ^a,e   Hallmans, Göran ^a   Jansson, Jan Håkan ^d  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e SUNDERBY HOSPITAL   (Sweden)

Author keywords

Acute myocardial infarction; C reactive protein; Cardiovascular risk factors; Cohort study; Endothelial cell markers

Indexed keywords

C REACTIVE PROTEIN; HEMOSTATIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH SURVEY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 68149176897     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832a5fd1     Document Type: Article

References (30)

1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107:499-511.
2. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammationand coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321:199-204.
3. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
4. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609-1616.
5. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003; 108:2323-2328.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
7. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29:439-493.
8. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
9. Thøgersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-2247.
10. Rautio A, Lundberg V, Messner T, Nasic S, Stegmayr B, Eliasson M. Favourable trends in the incidence and outcome of myocardial infarction in nondiabetic, but not in diabetic, subjects: findings from the MONICA myocardial infarction registry in northern Sweden in 1989-2000. J Intern Med 2005; 258:369-377.
11. Tunstall-Pedoe H, Kuulasmaa K, Mæhönen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37WHO MONICA Project. Lancet 1999; 353:1547-1557.
12. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implication for clinical and epidemiological applications. Clin Chem 2000; 46:461-468.
13. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32:2160-2165.
14. Rånby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost 1989; 61:409-414.
15. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 1998; 58:475-484.
16. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28:1356-1358.
17. Lundblad D, Dinesen B, Rautio A, Røder ME, Eliasson M. Low level of tissue plasminogen activator activity in nondiabetic patients with a first myocardial infarction. J Intern Med 2005; 258:13-20.
18. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 1998; 79:129-133.
19. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004; 109:1955-1959.
20. Cushman M, Arnold AM, Psaty B, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. The Cardiovascular Health Study. Circulation 2005; 112:25-31.
21. Ohsawa M, Okayama A, Nakamura M, Onoda T, Kato K, Itai K, et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med 2005; 41:651-656.
22. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352:1611-1613.
23. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264:295-314.
24. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17:1121-1127.
25. van der Meer IM, de Maat MPM, Kiliaan AJ, van der Kuip DAM, Hofman A, Witteman JCM. The value of C-reactive protein in cardiovascular risk prediction. Arch Intern Med 2003; 163:1323-1328.
26. Tall AR. C-reactive protein reassessed. N Engl J Med 2004; 350:1450-1452.
27. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
28. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease. Comparison of traditional and novel risk factors. JAMA 2005; 293:1737-1745.
29. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand J Clin Lab Invest 1999; 59 (Suppl 230):23-31.
30. Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP Project. Thromb Res2005; 116:223-232.